Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1038 • 2019 ACR/ARP Annual Meeting
Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus
Rebecca Schriefer ¹, Gabriel Arguelles ¹, John Atkinson ¹, Dennis Hourcade ¹ and Alfred Kim¹, ¹Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Cell-bound complement activation products (CB-CAPs) have previously been shown to associate with SLE disease activity, but only a small fraction of total CB-CAPs has…
Abstract Number: 1469 • 2019 ACR/ARP Annual Meeting
New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Florence Assan¹, Raphaele Seror ², Gaetane Nocturne ³ and Xavier Mariette ⁴, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ³Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: The new 2019 SLE EULAR/ACR Classification Criteria for Systemic lupus erythematosus (SLE) have been developed to find a better equilibrium between specificity and sensitivity…
Abstract Number: 1596 • 2019 ACR/ARP Annual Meeting
Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients
Lisa Zhu¹, Manpreet Singh ¹, Sonia Lele ¹, Mei Liang ², Lori Sahakian ¹, Jennifer Grossman ¹ and Maureen McMahon ¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Williams College, Williamstown, MA
Background/Purpose: It has been well established that patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease (CVD). Traditional CVD risk…
Abstract Number: 1728 • 2019 ACR/ARP Annual Meeting
Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Anthony Hoang ¹, Howard Yang ², Tracy Andrews ³, Jennifer Weiss ⁴, Kathleen Haines ⁴, Yukiko Kimura ⁵ and Suzanne Li⁴, ¹Rutgers University, New Brunswick, NJ, ²David Geffen School of Medicine at UCLA, Santa Monica, CA, ³Rutgers University, Newark, NJ, ⁴Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁵Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH
Background/Purpose: Avascular necrosis (AVN) is a serious comorbidity of juvenile systemic lupus erythematosus (jSLE) associated with disability, impaired quality of life, and increased cost of…
Abstract Number: 2021 • 2019 ACR/ARP Annual Meeting
Higher Genetic Risk Load in Patients with More Diverse Manifestations in a Korean Systemic Lupus Erythematosus Cohort
So-Young Bang¹, Eunji Ha ², Hyuk-Hee Kwon ³, Hyun-Seung Yoo ⁴, Juyeon Kang ¹, Ji-Soong Kim ¹, Bora Nam ¹, Jung-Min Shin ¹, Yeon-Kyung Lee ¹, Tae-Han Lee ⁵, Hye-Soon Lee ⁶, Kwangwoo Kim ² and Sang-Cheol Bae ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Kyung Hee University, Seoul, Republic of Korea, ³Hanyang University Hospital, Guri, ⁴Hanyang University Hospital, Guri, Republic of Korea, ⁵Hanyang University, Seoul, ⁶Department of Internal Medicine, Hanyang University Guri Hospital,Hanyang University School of Medicine, Guri, Korea, Guri, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with diverse heterogeneous phenotypes. Although many studies of SLE presented estimates of high heritability, impact…
Abstract Number: 2282 • 2019 ACR/ARP Annual Meeting
Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population
Kimberly Showalter¹, Melanie Smith ², Jonathan Cheah ², Nilasha Ghosh ², Elena Gkrouzman ², Sarah Lieber ², Sebastian Sattui ², Noa Schwartz ², Monica Schwartzman ², Jessica Berman ², Lisa Sammaritano ² and Anne Bass ³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Women of reproductive age with rheumatic diseases are often prescribed teratogenic medications; thus, reproductive counseling is important. A prior study demonstrated improvement in counseling…
Abstract Number: 2533 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Increases Low C3 in SLE
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hydroxychloroquine is considered an immunomodulatory that does not affect serology. Hydroxychloroquine (HCQ) was recently introduced into Japan. In SLE patients who started hydroxychloroquine, there…
Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting
Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Nicolle Medina-Cintrón¹, Ileana Vázquez-Otero ¹, Mariangelí Arroyo-Ávila ¹, Lorena González-Sepúlveda ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…
Abstract Number: 2815 • 2019 ACR/ARP Annual Meeting
Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus
John Mountz¹, Min Gao ², Qi Wu ³, PingAr Yang ², Alex Essman ⁴, Oluwagbemiga Ojo ⁴, Shanrun Liu ², Jake Chen ², Iñaki Sanz ⁵, W. Winn Chatham ² and Hui-Chen Hsu ², ¹University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁵Emory University, ATLANTA, GA
Background/Purpose: Studies to date have primarily focused on stimulators that are overexpressed and activate B cells in SLE subjects. Factors that can maintain B cells…
Abstract Number: 88 • 2019 ACR/ARP Annual Meeting
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
Irene Cecchi¹, Massimo Radin ¹, Elena Rubini ¹, Silvia Grazietta Foddai ¹, Ana Suarez ², Elisa Menegatti ¹, Dario Roccatello ¹, Savino Sciascia ³ and Javier Rodriguez Carrio ², ¹University of Turin, Turin, Italy, ²University of Oviedo, Oviedo, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Type I Interferons (IFN) play a key role in the pathogenesis and evolution of various autoimmune diseases. Previous studies have demonstrated that the expression…
Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Hayam ElAggan¹, Nahla Farahat ¹, Mohamed Sakr ¹ and Shaymaa Tawfik ¹, ¹Faculty of Medicine, University of Alexandria, Alexandria, Egypt, Alexandria, Egypt
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…
Abstract Number: 894 • 2019 ACR/ARP Annual Meeting
Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015
Miao Jiang ¹, Barnabas Desta ¹, Aimee Near ², Xia Wang ¹ and Edward Hammond¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: We evaluated the real-world frequency and severity of flares and associated costs 1 year post diagnosis in a US cohort with newly diagnosed SLE.Methods:…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1558 • 2019 ACR/ARP Annual Meeting
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Whitney Bembry¹, Dasha Lopez ², Christopher Mesa ³, Nirupa Patel ³ and Myriam Guevara ⁴, ¹Tulane University School of Medicine, New Orleans, LA, ²Baton Rouge General Hospital, Baton Rouge, LA, ³Louisiana State University School of Medicine, New Orleans, LA, ⁴Louisiana State University School of Medicine, New Orleans
Background/Purpose: Evidence of podocyte effacement on electron microscopy and significant proteinuria in a systemic lupus erythematosus (SLE) patient with biopsy proven minimal mesangial (MM), mesangial…
Abstract Number: 1597 • 2019 ACR/ARP Annual Meeting
Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes
Paramjit Singh¹, ¹Kaiser Permanente Fontana, Fontana
Background/Purpose: Systemic lupus erythematosus (SLE) is a significant risk factor for coronary atherosclerosis, independent of the classic risk factors. Previous studies have found poor acute…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].